VRCA vs SKIN vs PRGO vs ELF vs COTY

For growth investors, Verrica Pharmaceuticals Inc.

(VRCA) is the stronger pick with 370. 2% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). e. l. f. Beauty, Inc. (ELF) offers the better valuation at 32. 2x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate Verrica Pharmaceuticals Inc. (VRCA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, e.

l. f. Beauty, Inc. (ELF) delivered a total return of +105. 0%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: ELF returned +133. 1% versus VRCA's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Coty Inc.

(COTY) is the lower-risk stock at 1. 08β versus e. l. f. Beauty, Inc. 's 2. 36β — meaning ELF is approximately 118% more volatile than COTY relative to the S&P 500. On balance sheet safety, Verrica Pharmaceuticals Inc. (VRCA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verrica Pharmaceuticals Inc.

(VRCA) is pulling ahead at 370. 2% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: Verrica Pharmaceuticals Inc. grew EPS 88. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VRCA leads at 57. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

e.

l. f. Beauty, Inc. (ELF) is the more profitable company, earning 8. 5% net margin versus -50. 3% for Verrica Pharmaceuticals Inc. — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELF leads at 12. 0% versus -33. 6% for VRCA. At the gross margin level — before operating expenses — VRCA leads at 93. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 19. 9x for e. l. f. Beauty, Inc. — 14. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRCA: 106. 3% to $17. 00.

In this comparison, PRGO (9.

8% yield), COTY (0. 6% yield) pay a dividend. VRCA, SKIN, ELF do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Coty Inc.

(COTY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), 0. 6% yield). Verrica Pharmaceuticals Inc. (VRCA) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (COTY: -83. 0%, VRCA: -95. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VRCA (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and ELF (Consumer Defensive) and COTY (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VRCA is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; ELF is a small-cap high-growth stock; COTY is a small-cap quality compounder stock. PRGO, COTY pay a dividend while VRCA, SKIN, ELF do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.